Healthcare Equipment and Supplies
Company Overview of BioSig Technologies, Inc.
BioSig Technologies, Inc., a development stage medical device company, engages in developing a technology platform to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation. Its products under development includes PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP system, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The company is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists i...
8441 Wayzata Boulevard
Minneapolis, MN 55426
Founded in 2009
Key Executives for BioSig Technologies, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $385.8K
Co-Founder and Executive Chairman
Total Annual Compensation: $368.1K
Chief Financial Officer
Total Annual Compensation: $102.5K
Compensation as of Fiscal Year 2015.
BioSig Technologies, Inc. Key Developments
BioSig Technologies, Inc. Approves Amendment its Amended and Restated Certificate of Incorporation
Nov 25 16
On November 18, 2016 at the special meeting of BioSig Technologies, Inc., the stockholders approved an amendment to the company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 50,000,000 to 200,000,000 shares.
BioSig Technologies, Inc. Presents at LD Micro Main Event 2016, Dec-07-2016 11:30 AM
Nov 16 16
BioSig Technologies, Inc. Presents at LD Micro Main Event 2016, Dec-07-2016 11:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: Gregory D. Cash, Chief Executive Officer, President and Director.
BioSig Technologies, Inc. to Develop PURE EP™ System, a Novel Cardiac Electrophysiology Information System
Oct 27 16
BioSig Technologies, Inc. is developing the PURE EP™ System, a novel cardiac electrophysiology (EP) information system. The company's medical device product is on track to commercialization in 2017. The company's PURE EP™ System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system developed to assist electrophysiologists in making clinical decisions in real-time, albeit diagnostic or during an ablation procedure. Refined in collaboration with institutions such as the Texas Cardiac Arrhythmia Institute, Mayo Clinic, Mount Sinai and UCLA with data presented at world-renowned conferences, the PURE EP System has the potential to shorten procedure time and reduce the necessity for repeated procedures that are frequent with current devices. Recently, the PURE EP System was featured in an article written by researchers from the Mayo Clinic and published online in The Journal of the American College of Cardiology: Clinical Electrophysiology (JACCCEP). Many of EP systems have limited dynamic range, which translates into problems in needing to amplify small signals in order to see them, which ultimately distorts resolution and saturates large signals. Electrical noise is also an issue, which makes it difficult for clinicians to differentiate real physiologic signals from noise. BioSig's PURE EP System has shown effective in helping to solve these issues. Because the PURE EP qualifies with the FDA as a Class II medical device, extensive clinical trials are not required. The company plans to file for a 510(k) marketing clearance which creates a relatively short path to commercialization, and only requires the company to show the device to be safe and substantially equivalent to another product on the market. The company intends to file its 510(k) application in the first half of 2017.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 28, 2016